Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays
the progression of chronic kidney disease (CKD), its effect on patients with autosomal
dominant polycystic kidney dis...
www.kireports.org
March 26, 2025 at 5:42 PM
Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
www.jacc.org/doi/abs/10.1... I think the take home message here is "give more diuretics" but good to recap the different modalities, and I wonder if I under use tolvaptan?
March 27, 2025 at 7:45 AM
www.jacc.org/doi/abs/10.1... I think the take home message here is "give more diuretics" but good to recap the different modalities, and I wonder if I under use tolvaptan?
7/ Little data exists for those with CKD stage 5. How do you think tolvaptan will fare in such a population? We hope this article provides some answers!
August 28, 2025 at 2:59 AM
7/ Little data exists for those with CKD stage 5. How do you think tolvaptan will fare in such a population? We hope this article provides some answers!
Researchers determined that #tolvaptan should be considered as an alternative therapy for refractory #hyponatremia in cirrhosis. #kidneywk #nephsky
Case Report: Patient With Hyponatremia and Fontan-Associated Cardiac Cirrhosis | Docwire News
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
buff.ly
December 10, 2024 at 9:15 PM
Researchers determined that #tolvaptan should be considered as an alternative therapy for refractory #hyponatremia in cirrhosis. #kidneywk #nephsky
Alam retakes the stage for tolvaptan pro/con debate #CSNinAmerica
December 5, 2024 at 7:27 AM
Alam retakes the stage for tolvaptan pro/con debate #CSNinAmerica
The FDA has approved a generic version of the ADPKD drug tolvaptan. #adpkd #kidneydisease #genericdrugs #nephrology #nephsky www.docwirenews.com/post/fda-app...
FDA Approves Lupin’s Generic Tolvaptan Tablets | Docwire News
Lupin's generic tolvaptan tablets have been approved by the FDA to treat autosomal dominant polycystic kidney disease (ADPKD), providing an alternative to Otsuka's Jynarque.
www.docwirenews.com
May 9, 2025 at 1:16 PM
The FDA has approved a generic version of the ADPKD drug tolvaptan. #adpkd #kidneydisease #genericdrugs #nephrology #nephsky www.docwirenews.com/post/fda-app...
💡 Who should get #Tolvaptan in #ADPKD?
A stepwise approach to identifying rapid disease progression 📈
✔️ eGFR decline >3 ml/min/yr? Treat!
✔️ Imaging/genetic risk? Assess!
📊 @BMCNephrology
🔗 doi.org/10.1186/s128...
#Nephrology #Kidney #NephBlueSky
A stepwise approach to identifying rapid disease progression 📈
✔️ eGFR decline >3 ml/min/yr? Treat!
✔️ Imaging/genetic risk? Assess!
📊 @BMCNephrology
🔗 doi.org/10.1186/s128...
#Nephrology #Kidney #NephBlueSky
February 24, 2025 at 4:11 PM
💡 Who should get #Tolvaptan in #ADPKD?
A stepwise approach to identifying rapid disease progression 📈
✔️ eGFR decline >3 ml/min/yr? Treat!
✔️ Imaging/genetic risk? Assess!
📊 @BMCNephrology
🔗 doi.org/10.1186/s128...
#Nephrology #Kidney #NephBlueSky
A stepwise approach to identifying rapid disease progression 📈
✔️ eGFR decline >3 ml/min/yr? Treat!
✔️ Imaging/genetic risk? Assess!
📊 @BMCNephrology
🔗 doi.org/10.1186/s128...
#Nephrology #Kidney #NephBlueSky
“@eAJKD: Kidney Week 2012: http://wp.me/p1IgOp-w4”
My post on the BREAKTHROUGH result for tolvaptan and polycystic kidney disease
My post on the BREAKTHROUGH result for tolvaptan and polycystic kidney disease
Kidney Week 2012: Late Breaking Trials: TEMPO
We now have an effective medication for autosomal dominan...
http://wp.me/p1IgOp-w4”
December 7, 2024 at 10:46 PM
“@eAJKD: Kidney Week 2012: http://wp.me/p1IgOp-w4”
My post on the BREAKTHROUGH result for tolvaptan and polycystic kidney disease
My post on the BREAKTHROUGH result for tolvaptan and polycystic kidney disease
The impact of tolvaptan on the incidence of contrast-induced acute kidney injury and long ... - goo.gl/alerts/oamqAd #GoogleAlerts
(PDF) The impact of tolvaptan on the incidence of contrast-induced acute kidney injury and long-term prognosis in high-risk patients after coronary intervention
PDF | Objective To investigate the effect of low-dose tolvaptan combined with hydration on the incidence of contrast-induced acute kidney injury... | Find, read and cite all the research you need on R...
goo.gl
May 11, 2025 at 6:08 PM
The impact of tolvaptan on the incidence of contrast-induced acute kidney injury and long ... - goo.gl/alerts/oamqAd #GoogleAlerts
SBGrid's eLife paper received a citation in April from Sébastien Granier from Institut de Génomique Fonctionnelle - IGF in @natcomms.nature.com : Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.
Read more here: buff.ly/KBqUrr8
Read more here: buff.ly/KBqUrr8
Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin - Nature Communications
To help in the rational design of new compounds for treating hyponatremia and polycystic kidney disease, the authors solve cryo-EM structures of the G protein-coupled vasopressin type 2 receptor in…
buff.ly
May 15, 2025 at 4:08 PM
SBGrid's eLife paper received a citation in April from Sébastien Granier from Institut de Génomique Fonctionnelle - IGF in @natcomms.nature.com : Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.
Read more here: buff.ly/KBqUrr8
Read more here: buff.ly/KBqUrr8
Real-world data from 2 US centers show that 27% of ADPKD patients discontinued tolvaptan—10% due to aquaretic side effects. Most stayed on lower doses than in trials. Tolerability remains a major barrier, especially for women. Better strategies needed. #ADPKD #Tolvaptan
10.34067/KID.0000000816
10.34067/KID.0000000816
May 23, 2025 at 12:35 PM
Real-world data from 2 US centers show that 27% of ADPKD patients discontinued tolvaptan—10% due to aquaretic side effects. Most stayed on lower doses than in trials. Tolerability remains a major barrier, especially for women. Better strategies needed. #ADPKD #Tolvaptan
10.34067/KID.0000000816
10.34067/KID.0000000816
This week, we break down three major nephrology studies:
✅ Obinutuzumab’s role in lupus nephritis
✅ Best phosphate binders for dialysis patients
✅ Long-term effects of tolvaptan in ADPKD
#podocytetalk #Nephpearls #Nephrology #CKD
youtu.be/86pdnfUKlsA
✅ Obinutuzumab’s role in lupus nephritis
✅ Best phosphate binders for dialysis patients
✅ Long-term effects of tolvaptan in ADPKD
#podocytetalk #Nephpearls #Nephrology #CKD
youtu.be/86pdnfUKlsA
Episode 19 - Lupus nephritis, Phosphate Binders & Tolvaptan: Key Updates in Nephrology!
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
March 17, 2025 at 6:42 AM
This week, we break down three major nephrology studies:
✅ Obinutuzumab’s role in lupus nephritis
✅ Best phosphate binders for dialysis patients
✅ Long-term effects of tolvaptan in ADPKD
#podocytetalk #Nephpearls #Nephrology #CKD
youtu.be/86pdnfUKlsA
✅ Obinutuzumab’s role in lupus nephritis
✅ Best phosphate binders for dialysis patients
✅ Long-term effects of tolvaptan in ADPKD
#podocytetalk #Nephpearls #Nephrology #CKD
youtu.be/86pdnfUKlsA
Real-World Tolvaptan Use in Autosomal Dominant Polycystic Kidney Disease - Kidney360 - goo.gl/alerts/MHJXFq #GoogleAlerts
Real-World Tolvaptan Use in Autosomal Dominant Polycystic... : Kidney360
rowth in individuals with rapidly progressive ADPKD, but its long-term tolerability and effective implementation has yet to be studied, particularly in real-world clinical settings within the US.
Met...
goo.gl
April 24, 2025 at 4:59 AM
Real-World Tolvaptan Use in Autosomal Dominant Polycystic Kidney Disease - Kidney360 - goo.gl/alerts/MHJXFq #GoogleAlerts
トルバプタン(サムスカ®︎)
日本で開発された新しい利尿薬。水だけを体外に排出する作用を持ち、ミネラルの喪失を防ぐ。
自称“水だけ滴るいい薬女(ファーガル)”
Tolvaptan-chan is a diuretic that originated in Japan. She has the effect of draining only water out of the body and calls herself “only waterdrop-dead gorgeous".
日本で開発された新しい利尿薬。水だけを体外に排出する作用を持ち、ミネラルの喪失を防ぐ。
自称“水だけ滴るいい薬女(ファーガル)”
Tolvaptan-chan is a diuretic that originated in Japan. She has the effect of draining only water out of the body and calls herself “only waterdrop-dead gorgeous".
February 9, 2024 at 7:59 AM
トルバプタン(サムスカ®︎)
日本で開発された新しい利尿薬。水だけを体外に排出する作用を持ち、ミネラルの喪失を防ぐ。
自称“水だけ滴るいい薬女(ファーガル)”
Tolvaptan-chan is a diuretic that originated in Japan. She has the effect of draining only water out of the body and calls herself “only waterdrop-dead gorgeous".
日本で開発された新しい利尿薬。水だけを体外に排出する作用を持ち、ミネラルの喪失を防ぐ。
自称“水だけ滴るいい薬女(ファーガル)”
Tolvaptan-chan is a diuretic that originated in Japan. She has the effect of draining only water out of the body and calls herself “only waterdrop-dead gorgeous".
I have a patient on tolvaptan for ADPKD. He is on 90 mg a day! Holy Sh*t that's a lot of tolvaptan.
Can't believe his sodium is only 137.
Can't believe his sodium is only 137.
December 8, 2024 at 6:32 AM
I have a patient on tolvaptan for ADPKD. He is on 90 mg a day! Holy Sh*t that's a lot of tolvaptan.
Can't believe his sodium is only 137.
Can't believe his sodium is only 137.
Inactive structures of the vasopressin V2 receptor reveal distinct antagonist binding modes for Tolvaptan and Mambaquaretin toxin https://www.biorxiv.org/content/10.1101/2024.11.20.624478v1
Inactive structures of the vasopressin V2 receptor reveal distinct antagonist binding modes for Tolvaptan and Mambaquaretin toxin https://www.biorxiv.org/content/10.1101/2024.11.20.624478v1
Antagonists of the arginine-vasopressin (AVP) V2 receptor (V2R) are key therapeutic compounds to tre
www.biorxiv.org
November 22, 2024 at 5:01 AM
Inactive structures of the vasopressin V2 receptor reveal distinct antagonist binding modes for Tolvaptan and Mambaquaretin toxin https://www.biorxiv.org/content/10.1101/2024.11.20.624478v1
10/n hepatoxicity of high-dose tolvaptan was observed in the ADPKD trials. Thus, should be avoided in ACLF and used w/caution otherwise. In SALTWATER, pts with ESLD took it for ~2 yrs w/o reported complications. https://pubmed.ncbi.nlm.nih.gov/20185637/
Oral tolvaptan is safe and effective in chronic hyponatre...
Vasopressin antagonists increase the serum sodium concent...
pubmed.ncbi.nlm.nih.gov
December 10, 2024 at 12:26 PM
10/n hepatoxicity of high-dose tolvaptan was observed in the ADPKD trials. Thus, should be avoided in ACLF and used w/caution otherwise. In SALTWATER, pts with ESLD took it for ~2 yrs w/o reported complications. https://pubmed.ncbi.nlm.nih.gov/20185637/
#AskRenal is this the best article on predicting response to tolvaptan in hyponatremia? @VelezNephHepato
https://www.ncbi.nlm.nih.gov/pubmed/29478867
https://www.ncbi.nlm.nih.gov/pubmed/29478867
Rapidity of Correction of Hyponatremia Due to Syndrome of...
Baseline serum sodium and SUN values are predictive of th...
www.ncbi.nlm.nih.gov
December 2, 2024 at 2:16 AM
#AskRenal is this the best article on predicting response to tolvaptan in hyponatremia? @VelezNephHepato
https://www.ncbi.nlm.nih.gov/pubmed/29478867
https://www.ncbi.nlm.nih.gov/pubmed/29478867
Sometimes they’ll even instruct you to try a medication that does the exact opposite of the one that was prescribed to you, for instance denying tolvaptan (inhibits ADH, *very expensive*) and insisting you try and fail Desmopressin (synthetic form of ADH, very cheap) first.
October 4, 2024 at 3:21 PM
Sometimes they’ll even instruct you to try a medication that does the exact opposite of the one that was prescribed to you, for instance denying tolvaptan (inhibits ADH, *very expensive*) and insisting you try and fail Desmopressin (synthetic form of ADH, very cheap) first.
PBFluids► I don't often use tolvaptan for hyponatremia...: ...but when I do I want it to work like this: http://bit.ly/22hCwcn
Page not found – Precious Bodily Fluids
bit.ly
December 4, 2024 at 11:56 PM
PBFluids► I don't often use tolvaptan for hyponatremia...: ...but when I do I want it to work like this: http://bit.ly/22hCwcn
6/ Intro
💡 Vasopressin has been implicated in cyst enlargement and kidney deterioration
💡 Multiple RCTs (TEMPO 3:4 and REPRISE) have found tolvaptan, a vasopressin receptor antagonist, to be effective in blunting kidney decline in CKD stage 4 and lower.
🔊https://www.nephjc.com/news/reprise
💡 Vasopressin has been implicated in cyst enlargement and kidney deterioration
💡 Multiple RCTs (TEMPO 3:4 and REPRISE) have found tolvaptan, a vasopressin receptor antagonist, to be effective in blunting kidney decline in CKD stage 4 and lower.
🔊https://www.nephjc.com/news/reprise
August 28, 2025 at 2:59 AM
6/ Intro
💡 Vasopressin has been implicated in cyst enlargement and kidney deterioration
💡 Multiple RCTs (TEMPO 3:4 and REPRISE) have found tolvaptan, a vasopressin receptor antagonist, to be effective in blunting kidney decline in CKD stage 4 and lower.
🔊https://www.nephjc.com/news/reprise
💡 Vasopressin has been implicated in cyst enlargement and kidney deterioration
💡 Multiple RCTs (TEMPO 3:4 and REPRISE) have found tolvaptan, a vasopressin receptor antagonist, to be effective in blunting kidney decline in CKD stage 4 and lower.
🔊https://www.nephjc.com/news/reprise
Samsca (tolvaptan) rep brought lunch. The 1st oral ADH antagonist for hyponatremia costs $250/pill. What's demeclocycline? $0.30/pill?
December 9, 2024 at 2:47 AM
Samsca (tolvaptan) rep brought lunch. The 1st oral ADH antagonist for hyponatremia costs $250/pill. What's demeclocycline? $0.30/pill?
Pt w/ undifferentiated cancer and severe SIADH - initial Na 117. Successful improvement with HTS. Despite fluid restriction, urea, diuretics, Na kept falling. Start tolvaptan and it works like a charm! Nothing made her happier than liberating her fluid restriction. #tolvaptanfan
November 17, 2024 at 2:10 AM
Pt w/ undifferentiated cancer and severe SIADH - initial Na 117. Successful improvement with HTS. Despite fluid restriction, urea, diuretics, Na kept falling. Start tolvaptan and it works like a charm! Nothing made her happier than liberating her fluid restriction. #tolvaptanfan